| 12 | 0 | 19 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨替吉奥联合阿帕替尼及卡瑞利珠单抗治疗晚期老年胃癌的近期疗效及安全性。方法 收集采用替吉奥联合阿帕替尼及卡瑞利珠单抗治疗的40例晚期老年胃癌患者为研究组，同期收治替吉奥联合阿帕替尼治疗的38例晚期老年胃癌患者为对照组，记录并评价两组近期疗效，治疗前后血清肿瘤标志物[糖类抗原(CA)199、CA72-4、癌胚抗原(CEA)、基质细胞衍生因子(SDF)-1]水平、免疫功能指标[免疫球蛋白(Ig)A、IgM、CD3+、CD4+、CD4+/CD8+]的变化及治疗过程中的毒副反应。结果 研究组客观缓解率(ORR)、疾病控制率(DCR)显著高于对照组，无进展生存期(PFS)和总生存期(OS)均较对照组显著延长(P<0.05);治疗后两组血清CA199、CA72-4、CEA及SDF-1浓度均较治疗前显著降低，且研究组较对照组降低更显著(P<0.05)。治疗后研究组IgA、IgM、CD3+、CD4+、CD4+/CD8+水平明显高于对照组(P<0.05),两组治疗后IgA、IgM明显低于治疗前，CD3+、CD4+、CD4+/CD8+水平均明显高于治疗前(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论 替吉奥联合阿帕替尼及卡瑞利珠单抗治疗晚期老年胃癌能提高近期疗效及延长远期生存时间，下调患者血清相关肿瘤标志物的表达水平，改善免疫功能指标，安全性良好，并不增加毒副反应的发生风险。
Abstract：1 López MJ,Carbajal J,Alfaro AL,et al.Characteristics of gastric cancer around the world[J].Crit Rev Oncol Hematol,2023;181:103841.
2 Xu B,He P,Wang Y,et al.PDT for gastric cancer-the view from China[J].Photodiagnosis Photodyn Ther,2023;42:103366.
3 郑荣寿，张思维，孙可欣，等.2016年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2023;45(3):212-20.
4 Li Y,Ren N,Zhang B,et al.Gastric cancer incidence trends in China and Japan from 1990 to 2019:disentangling age-period-cohort patterns[J].Cancer,2023;129(1):98-106.
5 Feng R,Su Q,Huang X,et al.Cancer situation in China:what does the China cancer map indicate from the first national death survey to the latest cancer registration[J]?Cancer Commun(Lond),2023;43(1):75-86.
6 Qiu H,Cao S,Xu R.Cancer incidence,mortality,and burden in China:a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J].Cancer Commun(Lond),2021;41(10):1037-48.
7 Ojima T,Nakamura M,Hayata K,et al.Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer:a randomized clinical trial[J].JAMA Surg,2021;156(10):954-63.
8 陈铁，江晓晖，高志斌，等.恒温热灌注联合常规化疗对老年胃癌术后病人免疫功能，相关因子及生存情况的影响[J].实用老年医学，2020;34(3):254-7.
9 尹航.老年胃癌放化疗患者血小板减少发生的相关因素[J].中国老年学杂志，2023;43(12):2856-8.
10 Japanese Gastric Cancer Association.Japanese gastric cancer treatment guidelines 2021(6th edition)[J].Gastric Cancer,2023;26(1):1-25.
11 Alsina M,Arrazubi V,Diez M,et al.Current developments in gastric cancer:from molecular profiling to treatment strategy[J].Nat Rev Gastroenterol Hepatol,2023;20(3):155-70.
12 Racz K,Legner A,Böhme F,et al.Magenkarzinom[Gastric cancer][J].Wien Med Wochenschr,2023;173(9-10):227-31.
13 Huang RJ,Laszkowska M,In H,et al.Controlling gastric cancer in a world of heterogeneous risk[J].Gastroenterology,2023;164(5):736-51.
14 Alagesan P,Goodwin JC,Garman KS,et al.Cancer progress and priorities:gastric cancer[J].Cancer Epidemiol Biomarkers Prev,2023;32(4):473-86.
15 Araújo D,Ribeiro E,Amorim I,et al.Repurposed drugs in gastric cancer[J].Molecules,2022;28(1):319.
16 阙志鹏，林双明，谢润，等.进展期胃癌老年患者术后辅助化疗完成情况的影响因素分析[J].中华老年医学杂志，2023;42(10):1213-7.
17 Yoshinami Y,Shoji H.Recent advances in immunotherapy and molecular targeted therapy for gastric cancer[J].Future Sci OA,2023;9(2):FSO842.
18 Bao SS,Tang PF,Gao NY,et al.Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats[J].Peer J,2023;11:e16051.
19 梁春燕，胡秀芳.阿帕替尼治疗晚期胃癌的临床疗效观察[J].肿瘤基础与临床，2023;36(5):432-5.
20 Borgeaud M,Sandoval J,Obeid M,et al.Novel targets for immune-checkpoint inhibition in cancer[J].Cancer Treat Rev,2023;120:102614.
基本信息:
中图分类号:R735.2
引用信息:
[1]王国平,曾守琼,张燕.替吉奥联合阿帕替尼及卡瑞利珠单抗治疗晚期老年胃癌效果及安全性[J].中国老年学杂志,2026,46(10):1737-1740.
基金信息:
四川省卫生健康委科研课题(110049)
2026-05-22
2026-05-22